Abstract：
OBJECTIVE: To evaluate the aspartate aminotransferase to platelet ratio (APRI) score as a predictive and prognostic test in intrahepatic cholestasis of pregnancy (ICP).
METHODS: This study was conducted in 198 patients diagnosed with ICP and 204 healthy pregnant women who presented to a tertiary center between 2019 and 2022. APRI scores; laboratory findings in the first, second, and third trimesters; and perinatal outcomes were compared between the two groups. The ICP group was evaluated for correlation between APRI scores and composite adverse outcomes. Two different receiver operating characteristic analyses were performed to determine optimal cutoff values of predictive APRI score of ICP and composite adverse outcomes in patients with ICP.
RESULTS: Aspartate aminotransferase values and APRI scores were significantly higher in the ICP group in all trimesters (P < 0.001). The optimal cutoff values of APRI scores to predict ICP for the first, second, and third trimesters were 0.101 (79.7% sensitivity, 79.6% specificity), 0.103 (78.4% sensitivity, 76.3% specificity), and 0.098 (72.5% sensitivity, 72% specificity), respectively. APRI scores were statistically higher in patients with ICP with composite adverse outcomes in all trimesters (P values of 0.03, 0.04, and 0.01, respectively).
CONCLUSIONS: APRI score was found to be a valuable predictor of ICP and its adverse outcomes during the entire pregnancy.
METHODS: This study was conducted in 198 patients diagnosed with ICP and 204 healthy pregnant women who presented to a tertiary center between 2019 and 2022. APRI scores; laboratory findings in the first, second, and third trimesters; and perinatal outcomes were compared between the two groups. The ICP group was evaluated for correlation between APRI scores and composite adverse outcomes. Two different receiver operating characteristic analyses were performed to determine optimal cutoff values of predictive APRI score of ICP and composite adverse outcomes in patients with ICP.
RESULTS: Aspartate aminotransferase values and APRI scores were significantly higher in the ICP group in all trimesters (P < 0.001). The optimal cutoff values of APRI scores to predict ICP for the first, second, and third trimesters were 0.101 (79.7% sensitivity, 79.6% specificity), 0.103 (78.4% sensitivity, 76.3% specificity), and 0.098 (72.5% sensitivity, 72% specificity), respectively. APRI scores were statistically higher in patients with ICP with composite adverse outcomes in all trimesters (P values of 0.03, 0.04, and 0.01, respectively).
CONCLUSIONS: APRI score was found to be a valuable predictor of ICP and its adverse outcomes during the entire pregnancy.
摘要：
目的：评价谷草转氨酶与血小板比值(APRI)评分对妊娠期肝内胆汁淤积症(ICP)的预测和预后评估价值。
方法：这项研究是在2019年至2022年期间到三级中心就诊的198名诊断为ICP的患者和204名健康孕妇中进行的。APRI评分；第一个实验室发现，第二,和妊娠晚期；比较两组的围产期结局。评估ICP组的APRI评分与复合不良结局之间的相关性。进行了两种不同的受试者工作特征分析，以确定ICP的预测APRI评分和ICP患者的复合不良结局的最佳临界值。
结果：在所有三个月中，ICP组的天冬氨酸转氨酶值和APRI评分均显着较高（P<0.001）。预测ICP的APRI分数的最佳临界值为第一，第二,妊娠晚期为0.101(灵敏度为79.7%，79.6%的特异性)，0.103（灵敏度为78.4%，76.3%特异性)，和0.098（灵敏度为72.5%，72%的特异性)，分别。在所有三个月中，具有复合不良结局的ICP患者的APRI评分在统计学上较高（P值分别为0.03、0.04和0.01）。
结论：发现APRI评分是整个妊娠期间ICP及其不良结局的有价值的预测因子。
方法：这项研究是在2019年至2022年期间到三级中心就诊的198名诊断为ICP的患者和204名健康孕妇中进行的。APRI评分；第一个实验室发现，第二,和妊娠晚期；比较两组的围产期结局。评估ICP组的APRI评分与复合不良结局之间的相关性。进行了两种不同的受试者工作特征分析，以确定ICP的预测APRI评分和ICP患者的复合不良结局的最佳临界值。
结果：在所有三个月中，ICP组的天冬氨酸转氨酶值和APRI评分均显着较高（P<0.001）。预测ICP的APRI分数的最佳临界值为第一，第二,妊娠晚期为0.101(灵敏度为79.7%，79.6%的特异性)，0.103（灵敏度为78.4%，76.3%特异性)，和0.098（灵敏度为72.5%，72%的特异性)，分别。在所有三个月中，具有复合不良结局的ICP患者的APRI评分在统计学上较高（P值分别为0.03、0.04和0.01）。
结论：发现APRI评分是整个妊娠期间ICP及其不良结局的有价值的预测因子。
